bonyf pivots back to own brands with PerioCream rollout

bonyf NV is shifting its strategy toward proprietary brands and plans the first commercial launches of PerioCream in five European markets in September 2026. The company also is targeting a U.S. entry for the periodontal care product, pending FDA clearance, as it seeks simpler operations and broader international growth.

Why it matters: - bonyf is trying to rebuild around its own brands after years of leaning more heavily on private-label work for third parties. - The strategy could make the company easier to market, easier to understand and more focused on products it fully controls. - PerioCream is positioned as the centerpiece of that shift and as a new growth driver in international dental care.

What happened: - bonyf NV said it is entering what it calls the “Renaissance of bonyf,” a strategic reset centered on proprietary products and international brand expansion. - The company said the transformation is a return to the entrepreneurial, brand-first model that defined its strongest years between 1980 and 2000. - First commercial launches of PerioCream are planned for September 2026 in Italy, Poland, Spain, Croatia and Slovenia. - bonyf said it is also in discussions with potential distributors in several additional markets. - The company said the U.S. is one of the most important future markets for PerioCream, with entry potentially before the end of 2026 if FDA clearance is obtained.

The details: - bonyf described PerioCream as an innovative high-end product for professional periodontal care. - The company said its earlier business mix included developing, manufacturing and marketing its own products, while private-label manufacturing played only a limited role. - bonyf said market changes and strategic decisions over time shifted commercial attention away from its own brands and toward private-label manufacturing and external product development. - The company said that shift made the business more complex and reduced focus on the international development of its proprietary brands. - bonyf said it is progressively refocusing resources on the marketing and international distribution of its own products. - The company said the goal is a more focused, recognizable and value-driven portfolio. - CEO Jean-Pierre Bogaert said the company is returning to the principles that made bonyf successful during its golden years, including innovation, strong proprietary products and direct investment in its own brands. - Bogaert said PerioCream is an important part of the renewed strategy and pointed to a growing international pipeline. - bonyf said the timing of any U.S. launch will depend on the progress and outcome of the regulatory process. - The company said the transformation is intended to simplify its commercial model, strengthen visibility for its proprietary brands and support sustainable international growth. - bonyf included a LinkedIn link in the release: the company's social media page

Between the lines: - The move signals a deliberate retreat from a more complicated, partner-driven model and a bet that ownership of products and brands will create better long-term value. - The U.S. plan matters because FDA clearance would open a much larger market, but the launch timing remains uncertain. - The European rollout suggests bonyf wants to prove PerioCream in multiple markets early, which could help distributor talks elsewhere.

What's next: - bonyf plans to begin the first PerioCream launches in September 2026 across five European countries. - The company will continue distributor discussions in other markets as it expands the pipeline. - FDA clearance will determine whether the U.S. launch can happen before the end of 2026. - bonyf said it will keep investing in its proprietary brands as part of the broader turnaround.